The Companion Diagnostics Market is expanding due to rising adoption of personalized medicine, targeted therapies, and advanced molecular diagnostics. With applications across oncology, cardiovascular, and infectious diseases, the market is projected to reach USD 26 billion by 2033 at a CAGR of 12.5%.
A companion diagnostic is a type of test designed to ensure the safe & effective use of a particular biological product or drug. They are used in cancer diagnosis to identify biomarkers to recommend the most appropriate drug, which allows for personalized treatment according to the specific condition of each patient. The global companion diagnostics market refers to the market in the healthcare industry, which is primarily centered on diagnostic methods utilized by patients affected by numerous medical conditions.
